- Abbvie: HSBC downgrades to hold from buy with a price target reduced from USD 167 to USD 156.
- Accenture: BNP Paribas Exane maintains a neutral recommendation with a price target raised from USD 280 to USD 345.
- Anglo American: AlphaValue/Baader Europe maintains its buy recommendation and reduces the target price from GBX 3094 to GBX 2864.
- Archer-Daniels-Midland: BMO Capital Markets downgrades to market perform from outperform with a price target reduced from USD 90 to USD 80.
- Astrazeneca: Baptista Research upgrades to outperform from hold with a price target reduced from USD 79.30 to USD 78.20.
- Bank Of New York Mellon: JP Morgan upgrades to overweight from neutral with a target price raised from USD 49 to USD 54.50.
- Blackrock: Deutsche Bank maintains its buy recommendation and raises the target price from USD 740 to USD 895.
- Blackstone: Deutsche Bank maintains its buy recommendation and raises the target price from USD 108 to USD 141.
- Block: JP Morgan maintains its overweight rating and raises the target price from USD 70 to USD 90.
- Chubb: Wells Fargo downgrades to equalweight from overweight with a price target reduced from USD 253 to USD 240.
- Citigroup: Daiwa Securities upgrades to buy from neutral with a price target raised from USD 43 to USD 63.
- Equifax: Jefferies upgrades to buy from hold with a price target raised from USD 200 to USD 315.
- Exelon: Morgan Stanley downgrades to equalwt from overwt with a price target reduced from USD 45 to USD 38.
- Fifth Third Bancorp: JP Morgan maintains a neutral recommendation with a price target raised from USD 26 to USD 34.50.
- Franklin Resources: Deutsche Bank maintains its hold recommendation and raises the target price from USD 24 to USD 30.
- Fresnillo: Morgan Stanley downgrades to underweight from equal weight with a target price reduced from GBX 620 to GBX 540.
- Gsk: HSBC maintains its reduce recommendation with a price target raised from 11.90 to GBP 12.
- Huntington Bancshares: RBC Capital maintains its outperform rating and raises the target price from USD 12 to USD 15.
- Illumina: Leerink Partners maintains its outperform recommendation and raises the target price from USD 140 to USD 170.
- Intel: DZ Bank AG Research maintains its hold recommendation with a price target raised from USD 38 to USD 48.
- Jpmorgan Chase: Daiwa Securities upgrades to buy from outperform with a price target raised from USD 167 to USD 200.
- Kkr & Co: Deutsche Bank maintains its buy recommendation and raises the target price from USD 92 to USD 114.
- M&T Bank: Deutsche Bank downgrades to hold from buy with a target price of USD 145.
- Mettler-Toledo International: Baptista Research upgrades to buy from hold with a price target raised from USD 1450 to USD 1491.40.
- Monolithic Power Systems: Deutsche Bank maintains its buy recommendation and raises the target price from USD 500 to USD 660.
- Northern Trust: Deutsche Bank maintains its hold recommendation and raises the target price from USD 65 to USD 80.
- Palo Alto Networks: Raymond James downgrades to market perform from outperform.
- Progressive: Wells Fargo upgrades to overweight from equalweight with a price target raised from USD 144 to USD 176.
- Prologis: JP Morgan upgrades to overweight from neutral with a price target raised from USD 123 to USD 148.
- Salesforce.com: Wolfe Research upgrades to outperform from peerperform with a target price of USD 315.
- Charles Schwab: Deutsche Bank maintains its buy recommendation and raises the target price from USD 66 to USD 84.
- Solaredge Technologies: Goldman Sachs downgrades to sell from neutral with a target price of USD 77.
- Truist Financial: JP Morgan maintains a neutral recommendation with a price target raised from USD 29 to USD 36.
- Unitedhealth Group: HSBC downgrades to reduce from hold with a price target reduced from USD 550 to USD 480.
- Unity Software: Jefferies maintains its hold recommendation and raises the target price from USD 23 to USD 36.
- Us Bancorp: JP Morgan maintains its overweight recommendation and raises the target price from USD 36 to USD 45.
- Welltower: JP Morgan upgrades to overweight from neutral with a target price raised from USD 92 to USD 99.